Oramed Pharmaceuticals Inc (ORMP.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2016||Chairman of the Board, Independent Director|
|43||2006||President, Chief Executive Officer, Director|
|2017||Chief Financial Officer, Treasurer, Secretary|
|46||2013||Chief Operating Officer, Vice President - Business Development|
|76||2006||Chief Scientific Officer, Director|
- BRIEF-Oramed receives approval for clinical study to treat NASH
- BRIEF-Oramed pharmaceuticals concludes its meeting with U.S. FDA regarding its oral insulin formulation
- BRIEF-Oramed Pharmaceuticals Inc's CFO Yifat Zommer resigned from her positions with co per personal reasons
- BRIEF-Oramed announces dual-listing on Tel Aviv stock exchange
- BRIEF-Oramed granted Japanese patent for combination insulin and glp-1 analog capsule